Share
clock Created with Sketch.
17/09/15
12:36
Share
Originally posted by Hoyland
↑
Maybe this rating helps to explain why Maxim's recent biotech IPO's don't seem to be as successful as other biotech IPO's?
The Regenxbio IPO, which is happening in the US overnight, should be a good indicator of what the market really thinks. If they can raise $121M with the Greek economic problems, the China currency problems and whatever other reasons that were given for Benitec's IPO performance, then we will know that we partnered with the wrong crowd. If Regenxbio falls well short of the $121M, then this would add credibility to the arguments made in Peter's BRR radio Q&A about the IPO.
Expand
Well is it an actual real IPO? How much percent of the company are they offering? How many clinical programs? How far long? I really don't see how you could compare the two if they are doing an actual IPO.